Region
CDMOs in Europe
Compare European CDMOs with EMA-compliant facilities across Germany, Switzerland, Ireland, and the broader EU. Filter by specialization, scale, and regulatory approvals.
926 companies listed
European CDMO Manufacturing
Europe is the second-largest pharma manufacturing region globally, with particular strengths in biologics, API synthesis, and sterile manufacturing. Germany leads in both volume and technological capability, followed by Switzerland (home to major CDMO headquarters), Ireland (a biologics manufacturing hub driven by favorable tax policy), and Italy (strong in API and generics).
EMA regulation provides mutual recognition advantages. A GMP certificate from one EU member state is recognized across the bloc, simplifying multi-market filings. The EMA also maintains Mutual Recognition Agreements (MRAs) with regulators in the US, Canada, Australia, Japan, and other markets, meaning European GMP inspections are often accepted by foreign authorities.
How does pricing compare? European CDMOs typically cost 10-30% more than Asian alternatives but offer shorter lead times for European and US sponsors, stronger IP protection, and established regulatory relationships. For high-value biologics and specialty products, the total cost of quality often favors European manufacturing.
Browse Europe CDMOs by country
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
Companies (926)
Imerys
France
Imerys is a global leader in mineral-based specialty solutions for industry. Its pharmaceutical-relevant operations include GMP-certified calcium carbonate API manufacturing. The company is FDA-registered for API manufacture and has been inspected by the FDA. Imerys primarily supplies raw mineral-based ingredients to the pharmaceutical industry rather than manufacturing finished drug products.
Viral Vectors
JSR Life Sciences (KBI Biopharma / Selexis)
Switzerland
JSR Life Sciences is the parent organization of KBI Biopharma (CDMO) and Crown Bioscience (CRO), plus Selexis (cell line development). KBI Biopharma is a biologics CDMO providing mammalian and microbial expression, process development, analytical development, and clinical through commercial GMP manufacturing. Crown Bioscience is a separate CRO arm focused on preclinical oncology. This entity spans CDMO and CRO, but the primary CDMO identity is through KBI Biopharma. FDA registered with 4 FEI numbers and 5 inspections (4 NAI, 1 VAI).
Biologics Drug Substance
Frequently Asked Questions
What are the advantages of European CDMOs?+
Strong regulatory framework with EMA GMP compliance recognized globally. Mutual Recognition Agreements reduce the need for duplicate inspections. Deep talent pool in biotechnology and chemistry. Proximity to European markets and established distribution networks. Strong intellectual property protection under EU law. Many European CDMOs also hold FDA registration for US-market products.
How does EMA regulation compare to FDA?+
Both agencies enforce cGMP standards, but the processes differ. EMA uses a centralized procedure for EU-wide marketing authorization with national agencies conducting GMP inspections. FDA directly inspects manufacturing facilities. The EMA-FDA MRA means each agency can rely on the other's inspection findings, reducing duplication. Key difference: EMA requires a Qualified Person (QP) for batch release -- a role that does not exist in the US system.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
